Metabolic control in children with type 1 diabetes. Pre-existing diabetes mellitus, type 1, in childbirth
Conditions
Interventions
Intervention group: In the intervention group, after selecting patients, a sample of mesenchymal stem cells will be injected intravenously at a rate of 3 million per kilogram of body weight, twice, 3
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 7 Years
Inclusion criteria
Inclusion criteria: Pediatric patients selected from 2 age groups: 5 to 7 years and over 7 years with type 1 diabetes Patients with type 1 diabetes who have at least one positive antibody out of the 5 types of antibodies identified in type 1 diabetes Patients who have had diabetes for less than 4 years Patients who themselves or their parents have given informed consent to the plan
Exclusion criteria
Exclusion criteria: Patients who do not have any positive antibodies related to type 1 diabetes Patients who have had diabetes for more than 4 years Patients who have a known immunodeficiency, are taking an immunomodulatory drug, or have frequent infectious diseases Patients who have a chronic systemic disease involving any organ of the body A patient who takes medication other than insulin on a regular basis A patient who has a different treatment protocol than the one mentioned in the plan implementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-Peptide. Timepoint: 3, 6, and 12 months after stem cell injection. Method of measurement: Parameter analysis using laboratory devices.;HbA1c. Timepoint: 3, 6, and 12 months after stem cell injection. Method of measurement: Parameter analysis using laboratory devices.;FBS. Timepoint: 3, 6, and 12 months after stem cell injection. Method of measurement: Parameter analysis using laboratory devices. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Farsinejad
Kerman University of Medical Sciences
Outcome results
None listed